Clinical, quality of life, and economic value of acromegaly disease control

Pituitary

Volumn 14, Issue 3, 2011, Pages 284-294

  Ben Shlomo, A ^a   Sheppard, M C ^b   Stephens, J M ^c   Pulgar, S ^d   Melmed, S ^a  

^a CEDARS SINAI MEDICAL CENTER   (United States)

^b UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^c PHARMERIT INTERNATIONAL   (United States)

^d NOVARTIS PHARMA AG   (Switzerland)

Author keywords

Acromegaly; Lanreotide; Morbidity; Mortality; Octreotide; Quality of life; Somatostatin analogues

Indexed keywords

ANGIOPEPTIN; BROMOCRIPTINE; DOPAMINE RECEPTOR STIMULATING AGENT; GROWTH HORMONE; OCTREOTIDE; PEGVISOMANT; SOMATOMEDIN C; SOMATOSTATIN DERIVATIVE;

ACROMEGALY; ARTHROPATHY; ARTICLE; ARTICULAR CARTILAGE; CARDIOVASCULAR DISEASE; COMORBIDITY; DIABETES MELLITUS; DISEASE CONTROL; ENDURANCE; EXERCISE TOLERANCE; HEALTH CARE COST; HEART LEFT VENTRICLE FUNCTION; HUMAN; HYPERTENSION; INSULIN RESISTANCE; LIPID METABOLISM; MORTALITY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROGNOSIS; QUALITY OF LIFE; SLEEP APNEA SYNDROME; VERTEBRA FRACTURE;

ACROMEGALY; HUMAN GROWTH HORMONE; HUMANS; INSULIN-LIKE GROWTH FACTOR I; OCTREOTIDE; PEPTIDES, CYCLIC; QUALITY OF LIFE; SOMATOSTATIN;

EID: 80053923341     PISSN: 1386341X     EISSN: 15737403     Source Type: Journal    
DOI: 10.1007/s11102-011-0310-7     Document Type: Article

References (64)

1. Melmed S (2006) Medical progress: acromegaly. N Engl J Med 355:2558-2573
2. Holdaway IM, Rajasoorya C (1999) Epidemiology of acromeg-aly. Pituitary 2:29-41
3. Reddy R, Hope S, Wass J (2010) Acromegaly. BMJ 341:c4189
4. Nachtigall L, Delgado A, Swearingen B, Lee H, Zerikly R, Klibanski A (2008) Changing patterns in diagnosis and therapy of acromegaly over two decades. J Clin Endocrinol Metab 93: 2035-2041 (Pubitemid 351831512)
5. Drange MR, Fram NR, Herman-Bonert V, Melmed S (2000) Pituitary tumor registry: a novel clinical resource. J Clin Endo-crinol Metab 85:168-174 (Pubitemid 32268809)
6. Biermasz NR, Roelfsema F, Pereira AM, Romijn JA (2009) Cost-effectiveness of lanreotide autogel in treatment algorithms of acromegaly. Expert Rev Pharmacoecon Outcomes Res 9:223-234
7. Petersenn S, Buchfelder M, Reincke M, Strasburger CM, Franz H, Lohmann R, Quabbe HJ, Plockinger U (2008) Results of surgical and somatostatin analog therapies and their combination in acromegaly: a retrospective analysis of the German acromeg-aly register. Eur J Endocrinol 159:525-532
8. Bex M, Abs R, T'Sjoen G, Mockel J, Velkeniers B, Muermans K, Maiter D (2007) AcroBel: the Belgian registry on acromegaly: a survey of the 'real-life' outcome in 418 acromegalic subjects. Eur J Endocrinol 157:399-409 (Pubitemid 350018442)
9. Mestron A, Webb SM, Astorga R, Benito P, Catala M, Gaz-tambide S, Gomez JM, Halperin I, Lucas-Morante T, Moreno B, Obiols G, De PP, Paramo C, Pico A, Torres E, Varela C, Vazquez JA, Zamora J, Albareda M, Gilabert M (2004) Epidemiology, clinical characteristics, outcome, morbidity and mortality in acromegaly based on the Spanish acromegaly registry (Registro Espanol de Acromegalia, REA). Eur J Endocrinol 151:439-446 (Pubitemid 39430260)
10. Melmed S, Colao A, Barkan A, Molitch M, Grossman AB, Kleinberg D, Clemmons D, Chanson P, Laws E, Schlechte J, Vance ML, Ho K, Giustina A (2009) Guidelines for acromegaly management: an update. J Clin Endocrinol Metab 94:1509-1517
11. Feelders RA, Hofland LJ, van Aken MO, Neggers SJ, Lamberts SW, de Herder WW, van der Lely A-J (2009) Medical therapy of acromegaly: efficacy and safety of somatostatin analogues. Drugs 69:2207-2226
12. Brada M, Ashley S, Ford D, Traish D, Burchell L, Rajan B (2002) Cerebrovascular mortality in patients with pituitary adenoma. Clin Endocrinol 57:713-717 (Pubitemid 36962997)
13. Minniti G, Gilbert DC, Brada M (2009) Modern techniques for pituitary radiotherapy. Rev Endocr Metab Disord 10:135-144
14. Beauregard C, Truong U, Hardy J, Serri O (2003) Long-term outcome and mortality after transsphenoidal adenomectomy for acromegaly. Clin Endocrinol 58:86-91 (Pubitemid 36098853)
15. Ayuk J, Clayton RN, Holder G, Sheppard MC, Stewart PM, Bates AS (2004) Growth hormone and pituitary radiotherapy, but not serum insulin-like growth factor-I concentrations, predict excess mortality in patients with acromegaly. J Clin Endocrinol Metab 89:1613-1617 (Pubitemid 38507910)
16. Trepp R, Stettler C, Zwahlen M, Seiler R, Diem P, Christ ER (2005) Treatment outcomes and mortality of 94 patients with acromegaly. Acta Neurochir 147:243-251
17. Kauppinen-Makelin R, Sane T, Reunanen A, Valimaki MJ, Niskanen L, Markkanen H, Loyttyniemi E, Ebeling T, Jaatinen P, Laine H, Nuutila P, Salmela P, Salmi J, Stenman UH, Viikari J, Voutilainen E (2005) A nationwide survey of mortality in acro-megaly. J Clin Endocrinol Metab 90:4081-4086
18. Abosch A, Tyrrell JB, Lamborn KR, Hannegan LT, Applebury CB, Wilson CB (1998) Transsphenoidal microsurgery for growth hormone-secreting pituitary adenomas: initial outcome and long-term results. J Clin Endocrinol Metab 83:3411-3418 (Pubitemid 28500865)
19. Biermasz NR, Dekker FW, Pereira AM, Van Thiel SW, Schutte PJ, Van DH, Romjin JA, Roelfsema F (2004) Determinants of survival in treated acromegaly in a single center: predictive value of serial insulin-like growth factor I measurements. J Clin Endocrinol Metab 89:2789-2796 (Pubitemid 38766367)
20. Holdaway IM (2007) Excess mortality in acromegaly. Horm Res 68(Suppl 5):166-172
21. Swearingen B, Barker FG, Katznelson L, Biller BM, Grinspoon S, Klibanski A, Moayeri N, Black PM, Zervas NT (1998) Long-term mortality after transsphenoidal surgery and adjunctive therapy for acromegaly. J Clin Endocrinol Metab 83:3419-3426 (Pubitemid 28500866)
22. Shimatsu A, Yokogoshi Y, Saito S, Shimizu N, Irie M (1998) Long-term survival and cardiovascular complications in patients with acromegaly and pituitary gigantism. J Endocrinol Invest 21(Suppl 8):55-57 (Pubitemid 128670368)
23. Holdaway IM, Bolland MJ, Gamble GD (2008) A meta-analysis of the effect of lowering serum levels of GH and IGF-I on mortality in acromegaly. Eur J Endocrinol 159:89-95
24. Dekkers OM, Biermasz NR, Pereira AM, Romijn JA, Van-denbroucke JP (2008) Mortality in acromegaly: a metaanalysis. J Clin Endocrinol Metab 93:61-67
25. Sherlock M, Reulen RC, Alonso AA, Ayuk J, Clayton RN, Sheppard MC, Hawkins MM, Bates AS, Stewart PM (2009) ACTH deficiency, higher doses of hydrocortisone replacement, and radiotherapy are independent predictors of mortality in patients with acromegaly. J Clin Endocrinol Metab 94:4216-4223
26. Colao A, Ferone D, Marzullo P, Lombardi G (2004) Systemic complications of acromegaly: epidemiology, pathogenesis, and management. Endocr Rev 25:102-152 (Pubitemid 38269977)
27. Vilar L, Naves LA, Costa SS, Abdalla LF, Coelho CE, Casulari LA (2007) Increase of classic and nonclassic cardiovascular risk factors in patients with acromegaly. Endocr Pract 13:363-372
28. Davi' MV, Dalle Carbonare L, Giustina A, Ferrari M, Frigo A, Lo Cascio V, Francia G (2008) Sleep apnoea syndrome is highly prevalent in acromegaly and only partially reversible after biochemical control of the disease. Eur J Endocrinol 159:533-540
29. Van Thiel SW, Bax JJ, Biermasz NR, Holman ER, Poldermans D, Roelfsema F, Lamb HJ, van der Wall EE, Smit JW, Romijn JA, Pereira AM (2005) Persistent diastolic dysfunction despite successful long-term octreotide treatment in acromegaly. Eur J Endocrinol 153:231-238 (Pubitemid 41167481)
30. Colao A, Marzullo P, Ferone D, Spinelli L, Cuocolo A, Bonaduce D, Salvatore M, Boerlin V, Lancranjan I, Lombardi G (2000) Cardiovascular effects of depot long-acting somatostatin analog sandostatin LAR in acromegaly. J Clin Endocrinol Metab 85:3132-3140
31. Colao A, Cannavo S, Marzullo P, Pivonello R, Squadrito S, Vallone G, Almoto B, Bichisao E, Trimarchi F, Lombardi G (2003) Twelve months of treatment with octreotide-LAR reduces joint thickness in acromegaly. Eur J Endocrinol 148:31-38
32. Bonadonna S, Mazziotti G, Nuzzo M, Bianchi A, Fusco A, De Marinis L, Giustina A (2005) Increased prevalence of radiological spinal deformities in active acromegaly: a cross-sectional study in postmenopausal women. J Bone Miner Res 20:1837-1844 (Pubitemid 41361885)
33. Tolis G, Angelopoulos NG, Katounda E, Rombopoulos G, Kaltzidou V, Kaltsas D, Protonotariou A, Lytras A (2006) Medical treatment of acromegaly: comorbidities and their reversibility by somatostatin analogs. Neuroendocrinology 83:249-257 (Pubitemid 44578879)
34. Ben-Shlomo A, Melmed S (2008) Somatostatin agonists for treatment of acromegaly. Mol Cell Endocrinol 286:192-198
35. Lombardi G, Galdiero M, Auriemma RS, Pivonello R, Colao A (2006) Acromegaly and the cardiovascular system. Neuroendo-crinology 83:211-217 (Pubitemid 44578874)
36. Matta MP, Caron P (2003) Acromegalic cardiomyopathy: a review of the literature. Pituitary 6:203-207 (Pubitemid 39127619)
37. Colao A, Marzullo P, Cuocolo A, Spinelli L, Pivonello R, Bon-aduce D, Salvatore M, Lombardi G (2003) Reversal of acrome-galic cardiomyopathy in young but not in middle-aged patients after 12 months of treatment with the depot long-acting somatostatin analogue octreotide. Clin Endocrinol 58:169-176 (Pubitemid 36194271)
38. Colao A, Spinelli L, Cuocolo A, Spiezia S, Pivonello R, di Somma C, Bonaduce D, Salvatore M, Lombardi G (2002) Cardiovascular consequences of early-onset growth hormone excess. J Clin Endocrinol Metab 87:3097-3104 (Pubitemid 34822871)
39. Hradec J, Kral J, Janota T, Krsek M, Hana V, Marek J, Malik M (1999) Regression of acromegalic left ventricular hypertrophy after lanreotide: a slow-release somatostatin analog. Am J Cardiol 83:1506-1509 (Pubitemid 29228354)
40. Baldelli R, Ferretti E, Jaffrain-Rea ML, Iacobellis G, Minniti G, Caracciolo B, Moroni C, Cassone R, Gulino A, Tamburrano G (1999) Cardiac effects of slow-release lanreotide: a slow-release somatostatin analog, in acromegalic patients. J Clin Endocrinol Metab 84:527-532 (Pubitemid 29075679)
41. Lombardi G, Colao A, Marzullo P, Biondi B, Palmieri E, Fazio S (2002) Improvement of left ventricular hypertrophy and arrhythmias after lanreotide-induced GH and IGF-I decrease in acromegaly. A prospective multi-center study. J Endocrinol Invest 25:971-976 (Pubitemid 36113282)
42. Colao A, Cuocolo A, Marzullo P, Nicolai E, Ferone D, Della Morte AM, Pivonello R, Salvatore M, Lombardi G (2001) Is the acromegalic cardiomyopathy reversible? Effect of 5-year normalization of growth hormone and insulin-like growth factor I levels on cardiac performance. J Clin Endocrinol Metab 86:1551-1557 (Pubitemid 32374902)
43. Colao A, Cuocolo A, Marzullo P, Nicolai E, Ferone D, Flori-Monte L, Salvatore M, Lombardi G (1999) Effects of 1-year treatment with octreotide on cardiac performance in patients with acromegaly. J Clin Endocrinol Metab 84:17-23 (Pubitemid 29036674)
44. Berg C, Petersenn S, Lahner H, Herrmann BL, Buchfelder M, Droste M, Stalla GK, Strasburger CJ, Roggenbuck U, Lehmann N, Moebus S, Jockel KH, Mohlenkamp S, Erbel R, Saller B, Mann K (2010) Cardiovascular risk factors in patients with uncontrolled and long-term acromegaly: comparison with matched data from the general population and the effect of disease control. J Clin Endocrinol Metab 95:3648-3656
45. Colao A, Lombardi G (1998) Growth-hormone and prolactin excess. Lancet 352:1455-1461 (Pubitemid 28510890)
46. Barkan A (1997) Acromegalic arthropathy and sleep apnea. J Endocrinol 155(Suppl 1):S41-S44
47. Colao A, Marzullo P, Vallone G, Marino V, Annecchino M, Ferone D, De Brasi D, Scarpa R, Oriente P, Lombardi G (1998) Reversibility of joint thickening in acromegalic patients: an ultrasonography study. J Clin Endocrinol Metab 83:2121-2125 (Pubitemid 28496347)
48. Colao A, Marzullo P, Vallone G, Giaccio A, Ferone D, Rossi E, Scarpa R, Smaltino F, Lombardi G (1999) Ultrasonographic evidence of joint thickening reversibility in acromegalic patients treated with lanreotide for 12 months. Clin Endocrinol 51: 611-618
49. Fatti LM, Scacchi M, Pincelli AI, Lavezzi E, Cavagnini F (2001) Prevalence and pathogenesis of sleep apnea and lung disease in acromegaly. Pituitary 4:259-262
50. Arosio M, Sartore G, Rossi CM, Casati G, Faglia G, Manzato E, Italian Multicenter Octreotide Study Group (2000) LDL physical properties, lipoprotein and Lp(a) levels in acromegalic patients. Effects of octreotide therapy. Atherosclerosis 151:551-557 (Pubitemid 30618774)
51. Delaroudis SP, Efstathiadou ZA, Koukoulis GN, Kita MD, Far-makiotis D, Dara OG, Goulis DG, Makedou A, Makris P, Slavakis A, Avramides AI (2008) Amelioration of cardiovascular risk factors with partial biochemical control of acromegaly. Clin Endocrinol 69:279-284 (Pubitemid 352009020)
52. Colao A, Marzullo P, Lombardi G (2002) Effect of a six-month treatment with lanreotide on cardiovascular risk factors and arterial intima-media thickness in patients with acromegaly. Eur J Endocrinol 146:303-309 (Pubitemid 34257639)
53. Hua SC, Yan YH, Chang TC (2006) Associations of remission status and lanreotide treatment with quality of life in patients with treated acromegaly. Eur J Endocrinol 155:831-837
54. Trepp R, Everts R, Stettler C, Fischli S, Allemann S, Webb SM, Christ ER (2005) Assessment of quality of life in patients with uncontrolled versus controlled acromegaly using the acromegaly quality of life questionnaire. Clin Endocrinol 63:103-110 (Pubitemid 40966410)
55. T'Sjoen G, Bex M, Maiter D, Velkeniers B, Abs R (2007) Health-related quality of life in acromegalic subjects: data from AcroBel, the Belgian registry on acromegaly. Eur J Endocrinol 157:411-417 (Pubitemid 350018443)
56. Matta MP, Couture E, Cazals L, Vezzosi D, Bennet A, Caron P (2008) Impaired quality of life of patients with acromegaly: control of GH/IGF-I excess improves psychological subscale appearance. Eur J Endocrinol 158:305-310 (Pubitemid 351404993)
57. Badia X, Webb SM, Prieto L, Lara N (2004) Acromegaly quality of life questionnaire. Health Qual Life Outcomes 2:13
58. Didoni G, Grottol S, Gasco V, Battistini M, Ferone D, Giusti M, Ragazzoni F, Ruffo P, Ghigo E, Minuto F (2004) Cost-of-illness study in acromegalic patients in Italy. J Endocrinol Invest 27:1034-1039
59. Luque-Ramírez M, Paramo C, da Varela CC, Garcia-Mayor RV (2007) Cost of management of invasive growth hormone-secreting macroadenoma. J Endocrinol Invest 30:541-545 (Pubitemid 47577805)
60. Murray CJ, Lopez AD (eds) (1996) The global burden of disease: a comprehensive assessment of mortality and disability from diseases, injuries, and risk factors in 1990 and projected to 2020. Harvard University Press, Cambridge
61. Tosteson AN, Burge RT, Marshall DA, Lindsay R (2008) Therapies for treatment of osteoporosis in US women: cost-effectiveness and budget impact considerations. Am J Manag Care 14:605-615
62. Lloyd-Jones D, Adams R, Carnethon M, De Simone G, Ferguson TB, Flegal K, Ford E, Furie K, Go A, Greenlund K, Haase N, Hailpern S, Ho M, Howard V, Kissela B, Kittner S, Lackland D, Lisabeth L, Marelli A, McDermott M, Meigs J, Mozaffarian D, Nichol G, O'Donnell C, Roger V, Rosamond W, Sacco R, Sorlie P, Stafford R, Steinberger J, Thom T, Wasserthiel-Smoller S, Wong N, Wylie-Rosett J, Hong Y (2009) Heart disease and stroke statistics-2009 update: a report from the American heart association statistics committee and stroke statistics subcommittee. Circulation 119:480-486
63. Kapur V, Blough DK, Sandblom RE, Hert R, de Maine JB, Sullivan SD, Psaty BM (1999) The medical cost of undiagnosed sleep apnea. Sleep 22:749-755 (Pubitemid 29445342)
64. Ray GT, Collin F, Lieu T, Fireman B, Colby CJ, Quesenberry CP, Van den Eeden SK, Selby JV (2000) The cost of health conditions in a health maintenance organization. Med Care Res Rev 57:92-109 (Pubitemid 30108936)